Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACP3 | P15309 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | IGFBP3 | P17936 | 2/20 | 0.39 |
| ▸ | IGFBP5 | P24593 | 1/20 | 0.39 |
| ▸ | PGK1 | P00558 | 1/20 | 0.39 |
| ▸ | PGK2 | P07205 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28992943 | 0.80 | ALOX15 (0.46) | KDM4EMEN1ALDH1A1CYP1A2GLA | |
| SCHEMBL4239380 | 0.77 | KDM4E (0.49) | KDM4EMEN1ALDH1A1CYP1A2GLA | |
| Hydrochloric Acid SCHEMBL9602865 | 0.76 | ALOX15 (0.50) | ACP3ALDH1A1HPGDHSD17B10ALOX15 | |
| SCHEMBL4241096 | 0.76 | DHODH (0.44) | KDM4EMEN1ALDH1A1CYP1A2GLA | |
| SCHEMBL4243783 | 0.75 | DHODH (0.45) | KDM4EMEN1ALDH1A1CYP1A2GLA | |
| SCHEMBL1202286 | 0.74 | ALOX15 (0.41) | KDM4EMEN1ALDH1A1CYP1A2GLA | |
| SCHEMBL1202536 | 0.72 | ALOX15 (0.40) | KDM4EMEN1ALDH1A1CYP1A2GLA | |
| SCHEMBL4768998 | 0.72 | KDM4E (0.52) | KDM4EMEN1ALDH1A1CYP1A2GLA | |
| SCHEMBL9327979 | 0.72 | IGFBP3 (0.52) | KDM4EMEN1ALDH1A1CYP1A2GLA | |
| SCHEMBL14769120 | 0.71 | ACP3 (0.54) | ACP3ALDH1A1PGK1PGK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8106043-B2 | Benzoxazines, benzothiazines, and related compounds having NOS inhibitory activity | NEURAXON, INC. (CA) | 2012-01-31 | — | — | US | disclosed |
| US-20110212947-A1 | SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON INC. (CA) | 2011-09-01 | — | — | US | disclosed |
| US-7989447-B2 | 1,5 and 3,6-substituted indole compounds having NOS inhibitory activity | NEURAXON, INC. (CA) | 2011-08-02 | — | — | US | disclosed |
| US-7951940-B2 | neuronal nitric oxide synthase (nNOS) isoform inhibitors; 2-ethyl-1-(1H-indol-5-yl)-isothiourea; neurogenerative disorders, stroke, reperfusion injury, head trauma, migraine headache, neuropathic pain, drug abuse, hyperalgesia | NEURAXON, INC. (CA) | 2011-05-31 | — | — | US | disclosed |
| US-7919510-B2 | treatment or prevention of chronic pain, acute pain, migraine, and neuropathic pain; selectively inhibits neuronal nitric oxide synthase (nNOS) over endothelial nitric oxide synthase (eNOS) and/or inducible nitric oxide synthase (iNOS) | NEURAXON, INC (CA) | 2011-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212947-A1 | SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NOS2, NOS1, NOS3 | ACP3 1922/4885KDM4E 2379/4885MEN1 3810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.